NCT04605926View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

June 30, 2021

Conditions
Coronavirus
Interventions
BIOLOGICAL

EQ001

itolizumab \[Bmab600\]

BIOLOGICAL

EQ001 Placebo

EQ001 Placebo

Trial Locations (1)

Unknown

Inv Site CO01, Medellín

Sponsors

Lead Sponsor

Equillium
All Listed Sponsors
collaborator

Biocon Limited

INDUSTRY

lead

Equillium

INDUSTRY

NCT04605926 - A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | Biotech Hunter | Biotech Hunter